SYSTEMATIC REVIEW OF THE ECONOMIC BURDEN OF ANTIBIOTIC RESISTANCE

X. Zhen,X. Hu,H. Dong

DOI: https://doi.org/10.1016/j.jval.2018.04.696

IF: 5.156

2018-01-01

Value in Health

Abstract:This study aims to systematically review and evaluate the evidence in order to determine the impact of antibiotic resistance on economic burden of patients. PubMed, Web of Science, and ScienceDirect databases were searched to identify relevant studies assessing the economic burden of antibiotic resistance. We included 90 eligible studies from the 5416 initially searched papers: nine both on gram negative organisms and gram positive organisms, 40 only on gram negative organisms, and 41 only on gram-positive organisms. 79 studies report the evidence from high-income countries, 48 of which are from the United States. The economic burden of antibiotic resistance were significantly higher for cases than controls for the total study population in 77 out of 90 studies. The costs difference was not statistically significant in 13 studies, most of which came from seriously ill patients or Methicillin resistant staphylococcus aureus cases. In addition, most studies agree that there is an association between antibiotic resistance and economic burden. The economic burden of patients with antibiotic resistance is alarmingly high, especially multi-drug resistance, while the paucity of evidence from non-high-income countries, the lack of prospective studies on large sample in multiple centers, and the short of studies on economic burden of antibiotic resistance from societal perspective warrant researchers' concern.